[The evaluation of the efficacy of adjuvant laferon therapy in the combined treatment of patients with ovarian cancer based on the monitoring of the tumor marker Ca-125 in the blood serum].
Relationship was established of blood level of CA-125 in patients with ovarian carcinoma (OC) to histologic form of tumour, with the highest CA-125 levels being recordable in patients with poorly differentiated OC, lower ones in those having serous form of OC, and the lowest in patients with mucinous form. Complex treatment schemes involving laferon make for striking and stable reduction of blood levels of CA-125 in patients presenting with serious and mucinous forms of OC and, strictly speaking, do not affect this same parameter in patients with poorly differentiated OC.
V Ie
VIe
Zhyl'chuk
O V
OV
Alistratov
A L
AL
Vorontsova
D002288:Adenocarcinoma, Mucinous / Q000097:blood / Q000188:drug therapy*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood*; D018394:CA-125 Antigen / Q000097:blood*; D002277:Carcinoma / Q000097:blood / Q000188:drug therapy*; D003131:Combined Modality Therapy; D016903:Drug Monitoring; D005260:Female; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D010051:Ovarian Neoplasms / Q000097:blood / Q000188:drug therapy*; D011994:Recombinant Proteins
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D018394:CA-125 Antigen; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins